Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

AVROBIO

NASDAQ AVRO
$1.39 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 28 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

62.26M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-35.17M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.37
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
44.79M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
2.21 %

Upcoming events AVROBIO

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart AVROBIO

Stock analysis AVROBIO

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
2.05 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
0.66 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.25 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-3.46 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
34.11 7.67

Price change AVROBIO per year

5.23$ 20.07$
Min Max

Summary analysis AVROBIO

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure AVROBIO

Revenue and net income AVROBIO

All parameters

Stock news AVROBIO

All news
30 January в 18:35

Avrobio Shares Dive 17% After Tectonic Therapeutic Deal

30 January в 18:30

Avrobio Shares Dive 17% After Tectonic Therapeutic Deal

30 January в 16:20

Avrobio to Merge With Tectonic Therapeutic in All-Stock Deal

30 January в 16:20

Avrobio to Merge With Tectonic Therapeutic in All-Stock Deal

12 July 2023 в 17:06

Avrobio Shares Rise 38% After Move to Explore Strategic Alternatives

12 July 2023 в 17:05

Avrobio Shares Rise 38% After Move to Explore Strategic Alternatives

12 July 2023 в 14:15

Avrobio to Explore Strategic Alternatives

12 July 2023 в 14:15

Avrobio to Explore Strategic Alternatives

22 May 2023 в 14:45

Avrobio Shares Rise 66% After Sale of Program to Novartis

22 May 2023 в 14:40

Avrobio Shares Rise 66% After Sale of Program to Novartis

18 May 2023 в 14:50

Avrobio Stock Up 16% on Positive Data for Cystinosis Treatment

18 May 2023 в 14:50

Avrobio Stock Up 16% on Positive Data for Cystinosis Treatment

1 May 2023 в 14:55

AVROBIO Down 4% as CEO Leaves, CFO Named Interim CEO

1 May 2023 в 14:55

AVROBIO Down 4% as CEO Leaves, CFO Named Interim CEO

18 October 2022 в 19:35

Avrobio Shares Rise 12% After ILAP Designation in U.K. for AVR-RD-02 Gene Therapy

18 October 2022 в 19:30

Avrobio Shares Rise 12% After ILAP Designation in U.K. for AVR-RD-02 Gene Therapy

20 September 2022 в 14:31

AvroBio Gets Rare Pediatric Disease Designation for AVR-RD-04 Cystinosis Treatment

20 September 2022 в 14:31

AvroBio Gets Rare Pediatric Disease Designation for AVR-RD-04 Cystinosis Treatment

17 May 2022 в 15:16

Avrobio Shares Rise on Encouraging Clinical Trial Data

17 May 2022 в 15:15

Avrobio Shares Rise on Encouraging Clinical Trial Data

About company AVROBIO

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Address:
Building 300, Cambridge, MA, United States, 02139
Company name: AVROBIO
Issuer ticker: AVRO
ISIN: US05455M1009
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-06-21
Sector: Healthcare
Industry: Biotechnology
Site: https://www.avrobio.com

On which stock exchange are AVROBIO (AVRO) stocks traded?

AVROBIO (AVRO) stocks are traded on NASDAQ.

What is the ticker of AVROBIO stocks (AVRO)?

The stock ticker of AVROBIO’s stocks or in other words, the code is AVRO. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does AVROBIO (AVRO) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, AVROBIO (AVRO) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are AVROBIO (AVRO) stocks traded?

AVROBIO (AVRO) stocks are traded on the NASDAQ exchange in dollars.

What is the price of AVROBIO (AVRO) stocks today?

The current price of AVROBIO stocks on 20.05.2024 is 1.39 dollars. per share.

What is the dynamics of AVROBIO (AVRO) stocks from the beginning of the year?

AVROBIO (AVRO) quotes have increased by -3.47% from the beginning of the year up to 1.39 dollars. per 1 stocks.

How much did AVROBIO (AVRO) stocks increase in мае 2024?

This month AVROBIO (AVRO) quotes have increased by 13.93% to 1.39 dollars. per share.

How much are AVROBIO (AVRO) stocks worth?

Today, on October, 20.05.2024 AVROBIO’s (AVRO) stocks cost 1.39 dollars..

What is the market capitalization of AVROBIO (AVRO)?

Capitalization is the market value of AVROBIO (AVRO) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of AVROBIO (AVRO) is estimated at about 62259490 dollars.